caused by pathogenic variants in the RAS/MAPK pathway, according to a study published in JACC: Basic to Translational Science. The study provides strong evidence for personalized treatment ...

"With the addition of VS-7375, a potential best-in-class oral KRAS G12D (ON/OFF) inhibitor, we are well-positioned to further establish our leadership in targeting RAS/MAPK pathway-driven cancers ...

We are a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. Our company was ...